NZ527391A - Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors - Google Patents

Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Info

Publication number
NZ527391A
NZ527391A NZ527391A NZ52739102A NZ527391A NZ 527391 A NZ527391 A NZ 527391A NZ 527391 A NZ527391 A NZ 527391A NZ 52739102 A NZ52739102 A NZ 52739102A NZ 527391 A NZ527391 A NZ 527391A
Authority
NZ
New Zealand
Prior art keywords
alkyl
alkanediyl
substituted
amino
het2
Prior art date
Application number
NZ527391A
Other languages
English (en)
Inventor
Dominique Louis Nest Surleraux
Piet Tom Bert Paul Wigerinck
Daniel Getman
Wim Gaston Verschueren
Sandrine Vendeville
Bethune Marie-Pierre De
Kerpel Jan Octaaf Antoon De
Samuel Leo Christiaan Moors
Kock Herman Augustinus De
Marieke Christiane Johan Voets
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NZ527391A publication Critical patent/NZ527391A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NZ527391A 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors NZ527391A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200529 2001-02-14
US28775801P 2001-05-02 2001-05-02
PCT/EP2002/001788 WO2002083657A2 (en) 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors

Publications (1)

Publication Number Publication Date
NZ527391A true NZ527391A (en) 2005-04-29

Family

ID=26076833

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527391A NZ527391A (en) 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Country Status (30)

Country Link
US (1) US7659404B2 (https=)
EP (1) EP1370543B1 (https=)
JP (1) JP4530612B2 (https=)
KR (1) KR100870184B1 (https=)
CN (2) CN100369904C (https=)
AP (1) AP1504A (https=)
AT (1) ATE343567T1 (https=)
AU (1) AU2002302363B2 (https=)
BG (1) BG66301B1 (https=)
BR (1) BR0207862A (https=)
CA (1) CA2438304C (https=)
CY (1) CY1108073T1 (https=)
CZ (1) CZ304273B6 (https=)
DE (1) DE60215623T2 (https=)
DK (1) DK1370543T3 (https=)
EA (1) EA006096B1 (https=)
EE (1) EE05385B1 (https=)
ES (1) ES2275866T3 (https=)
HR (1) HRP20030735B1 (https=)
HU (1) HU229224B1 (https=)
IL (2) IL157171A0 (https=)
MX (1) MXPA03007236A (https=)
NO (1) NO326174B1 (https=)
NZ (1) NZ527391A (https=)
PL (1) PL213327B1 (https=)
PT (1) PT1370543E (https=)
SI (1) SI1370543T1 (https=)
SK (1) SK287582B6 (https=)
WO (1) WO2002083657A2 (https=)
ZA (1) ZA200306086B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
EP1356082A2 (en) 2000-10-20 2003-10-29 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
AU2003202914A1 (en) 2002-01-07 2003-07-24 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
DE60321466D1 (de) 2002-07-01 2008-07-17 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
EP1520247B1 (en) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
CN1671380B (zh) * 2002-08-02 2010-05-26 泰博特克药品有限公司 广谱2-氨基-苯并噻唑磺酰胺类hiv蛋白酶抑制剂
OA12893A (en) * 2002-08-02 2006-10-13 Tibotec Pharm Ltd Broadspectrum 2-Amino-Benzothiazole Sulfonamide HIV Protease Inhibitors.
BRPI0414916A (pt) * 2003-09-30 2006-11-07 Tibotec Pharm Ltd métodos para a preparação de compostos de sulfonamida de benzoxazol e intermediários dos mesmos
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
US7378441B2 (en) * 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
DK1856125T3 (da) 2005-02-25 2009-12-07 Tibotec Pharm Ltd Syntese af proteasehæmmerforstadie
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
JO2841B1 (en) * 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9024038B2 (en) 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CN104000824B (zh) * 2014-05-28 2016-07-06 中山大学 苯并五元杂环类化合物在制备抗hiv-1病毒药物中的应用
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
CN116354903B (zh) * 2021-12-28 2025-09-09 南京药石科技股份有限公司 一种6-苯并噻唑磺酰氯的制备方法
WO2024206093A1 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation Hiv-1p rotease inhibitors and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0445926B1 (en) 1990-03-09 1996-08-21 Milliken Research Corporation Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2123065T3 (es) * 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
PT721331E (pt) 1993-10-01 2002-05-31 Astrazeneca Ab Processo i
CA2210889C (en) 1995-01-20 2007-08-28 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6140505A (en) * 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6861539B1 (en) * 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
BR9607625A (pt) 1995-03-10 1999-06-15 Searle & Co Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila
US6143788A (en) * 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
US5753660A (en) 1995-11-15 1998-05-19 G. D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
WO1997044014A1 (en) 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
SK284813B6 (sk) 1997-03-26 2005-12-01 Janssen Pharmaceutica N. V. Peleta obsahujúca itrakonazol, spôsob jej prípravy a farmaceutická dávková forma s jej obsahom
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
EA200000702A1 (ru) * 1997-12-24 2000-12-25 Вертекс Фармасьютикалз Инкорпорейтед Пролекарства ингибиторов аспартилпротеаз
PT1086076E (pt) 1998-06-19 2005-05-31 Vertex Pharma Inibidores de sulfonamida de aspartil protease
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
CA2872424C (en) * 1998-06-23 2017-03-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Bisfuran derivatives useful in preventing the emergence of multidrug resistant hiv strains and treatment of hiv
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Also Published As

Publication number Publication date
CN1525962A (zh) 2004-09-01
PT1370543E (pt) 2007-02-28
WO2002083657A3 (en) 2003-02-13
JP4530612B2 (ja) 2010-08-25
EE05385B1 (et) 2011-02-15
EE200300381A (et) 2003-12-15
CA2438304C (en) 2011-04-12
CY1108073T1 (el) 2014-02-12
HU229224B1 (en) 2013-09-30
NO326174B1 (no) 2008-10-13
CZ304273B6 (cs) 2014-02-12
EA200300891A1 (ru) 2004-02-26
EA006096B1 (ru) 2005-08-25
CN101230067A (zh) 2008-07-30
SI1370543T1 (sl) 2007-04-30
US20040116485A1 (en) 2004-06-17
PL213327B1 (pl) 2013-02-28
SK11022003A3 (sk) 2004-07-07
EP1370543B1 (en) 2006-10-25
HRP20030735B1 (en) 2012-02-29
PL363778A1 (en) 2004-11-29
AP2003002856A0 (en) 2003-09-30
AU2002302363B2 (en) 2008-05-01
AP1504A (en) 2005-12-10
NO20033584L (no) 2003-10-14
US7659404B2 (en) 2010-02-09
NO20033584D0 (no) 2003-08-13
BG66301B1 (bg) 2013-03-29
WO2002083657A2 (en) 2002-10-24
HUP0303257A2 (hu) 2004-01-28
DE60215623T2 (de) 2007-08-30
HRP20030735A2 (en) 2005-08-31
CZ20032415A3 (cs) 2004-04-14
EP1370543A2 (en) 2003-12-17
CN100369904C (zh) 2008-02-20
JP2004518767A (ja) 2004-06-24
ES2275866T3 (es) 2007-06-16
KR20030077017A (ko) 2003-09-29
CN101230067B (zh) 2011-06-15
IL157171A (en) 2012-10-31
CA2438304A1 (en) 2002-10-24
DK1370543T3 (da) 2007-02-19
MXPA03007236A (es) 2003-12-04
ATE343567T1 (de) 2006-11-15
IL157171A0 (en) 2004-02-08
SK287582B6 (sk) 2011-03-04
ZA200306086B (en) 2005-01-26
KR100870184B1 (ko) 2008-11-24
BR0207862A (pt) 2004-06-22
HK1061233A1 (en) 2004-09-10
DE60215623D1 (de) 2006-12-07
BG108143A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
NZ527391A (en) Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
ATE349417T1 (de) 5-aminolaevulinsäure-ester als mittel zur photosensibilisierung in der chemotherapie
MXPA03010258A (es) 2-amino-benzoxazol sulfonamidas, inhibidores de amplio espectro de la vih proteasa.
AR047744A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR059314A1 (es) Derivados de las benzamidas y heteroarenos
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
HRP20201089T1 (hr) Postupak sinteze inhibitora indolamin 2,3-dioksigenaze
HRP20191431T1 (hr) Postupak za pripravu (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida i njegovo pročišćavanje za uporabu kao aktivni farmaceutski pripravak
MXPA03009179A (es) 2-(amino sustituido)-benzoxazol sunfonamidas, inhibidores de amplio espectro de la vih proteasa.
MY135226A (en) Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
AR060267A1 (es) Tiazolil- dihidro -ciclopentapirazoles
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
TR200102523T2 (tr) Alkenil ve alkinil içeren metaloproteaz inhibitörleri
RU2008143546A (ru) Тиазолилдигидрохиназолины
MXPA04008929A (es) Benzimidazol sulfonamidas sustituidas como inhibidores de amplio espectro de la proteasa del vih.
NO20051291L (no) Bredspektrede substituerte oksindol-sulfonamid HIV-proteaseinhibitorer
TW200612946A (en) Combinations of substituted 1-phenyl-1,5-dihydro-pyrido-[3,2-b]indol-2-ones and other HIV inhibitors
AR045117A1 (es) Imidazo-pirimidinas y triazolo-pirimidinas:ligandos del receptor de benzodiazepina
TH85263A (th) สารยับยั้ง hiv โปรติเอส ที่เป็นเบนซิโซซาโซล ซัลโฟนามีด ที่ถูกแทนที่ สเปกตรัมกว้าง
TH76125A (th) ของผสมของ 1-ฟีนิล-1,5-ไดไฮโดร-ไพริโด[3,2-b]อินโดล-2-โอนชนิดถูกแทนที่และสารยับยั้ง hiv อื่นๆ
DE60303288D1 (de) Mmp-inhibitoren

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 14 FEB 2022 BY CPA GLOBAL

Effective date: 20140903

EXPY Patent expired